New Immune Strategy Turns Dead Cancer Cells Into Tumor-Fighting Weapons
Scientists engineered a fusion protein that recruits abundant immune cells to cross-present tumor antigens, boosting anticancer immunity in mice.
Summary
Cancer cells that die inside tumors leave behind debris that immune cells could theoretically use to mount an attack — but the specialized cells designed for this job are rarely present in tumors. Researchers at the Francis Crick Institute engineered a fusion protein called Fc-DNGR-1 that bridges F-actin, a protein exposed on dead cell surfaces, to Fcγ receptors found on far more abundant immune cells already inside tumors. This effectively recruited these common immune cells to do a job they normally cannot perform: ingesting necrotic debris and presenting tumor antigens to cancer-killing T cells. In mouse cancer models, this approach slowed tumor growth and worked even better when combined with chemotherapy or radiation, which generate more dead tumor cells.
Detailed Summary
Cancer immunotherapy has long relied on the body's ability to recognize and destroy tumor cells, but a key bottleneck limits this process: the specialized immune cells responsible for sounding the alarm — type 1 conventional dendritic cells, or cDC1s — are rare inside human and mouse tumors. Without enough of these cells, the immune system struggles to mount a full response even when tumors are full of dead, antigen-rich debris.
Researchers at the Francis Crick Institute set out to solve this scarcity problem by redirecting more common tumor-infiltrating immune cells to take over the job. Their strategy centered on DNGR-1, a receptor on cDC1s that naturally recognizes F-actin, a structural protein exposed on the surface of dead cells. By fusing DNGR-1 to an antibody Fc region, the team created a bifunctional molecule — Fc-DNGR-1 — that links dead-cell debris to Fcγ receptors expressed widely on other antigen-presenting cells including cDC2s and monocyte-derived cells.
In mouse tumor models, Fc-DNGR-1 accumulated at sites of necrosis within tumors and physically bridged dead cell material to surrounding Fcγ receptor-positive immune cells. These recruited cells were then able to cross-present tumor antigens to CD8+ T cells, a critical step in generating an active antitumor immune response.
The functional results were significant: F-actin–Fcγ receptor bridging enhanced tumor control in mice, and the effect was amplified when combined with cytotoxic chemotherapy or radiotherapy — both of which increase the availability of necrotic tumor material, essentially generating more substrate for the strategy to work with.
These findings introduce a novel immunotherapy concept: rather than trying to expand the scarce cDC1 population, harness the abundant immune cells already present in tumors by giving them the right molecular tools. Clinical translation will require human safety and efficacy studies, and the full paper details remain behind a paywall.
Key Findings
- Fc-DNGR-1 fusion protein redirects common tumor immune cells to ingest dead cancer cell debris and present antigens.
- The strategy bypasses scarcity of cDC1s by recruiting abundant cDC2s and monocyte-derived cells instead.
- Fc-DNGR-1 accumulated at necrotic tumor zones in close proximity to Fcγ receptor-positive immune cells in vivo.
- F-actin–FcγR bridging improved tumor control in mouse models and synergized with chemo- and radiotherapy.
- Anti-F-actin antibodies also replicated the bridging effect, suggesting multiple therapeutic formats are viable.
Methodology
The study used mouse cancer models to test Fc-DNGR-1 and anti-F-actin antibodies in vivo, evaluating tumor control, immune cell recruitment, and antigen cross-presentation. Combination experiments with cytotoxic chemotherapy and radiotherapy assessed synergistic effects. The summary is based on the abstract only, so full methodological details including specific tumor models and dosing are unavailable.
Study Limitations
This summary is based on the abstract only, as the full paper is not open access, limiting assessment of methodological rigor and data completeness. All efficacy data are from mouse models; human trials have not yet been reported. Several authors hold commercial interests in Adendra Therapeutics, which licenses the described technology, introducing potential conflicts of interest.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.